# US 2025/0145708 A1 · Epitope of Regulatory T Cell Surface Antigen and Antibody Specifically Binding Thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145708 A1
- Document ID: US20250145708A1
- Status: Published application
- Kind: A1
- Application number: 19/012,607
- Filed: 2025-01-07
- Published: 2025-05-08
- Earliest claimed: 2018-05-09
- Assignees: Good T Cells, Inc.
- Applicants: Good T Cells, Inc.
- Inventors: Jung Ho Kim; Beom Seok Kim
- Web page: https://patentgrep.com/patent/US20250145708A1

## CPC

- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to an epitope of leucine-rich and immunoglobulin-like domains 1 (Lrig-1) protein, which is an antigen present on the surface of regulatory T cells, and an antibody or antigen-binding fragment specifically binding thereto.

## Claims

### Claim 1

A method for preventing or treating cancer by decreasing phosphorylation of STAT3, the method comprising administering, to an individual, an antibody or antigen-binding fragment thereof that specifically binds to the Lrig-1 protein, the antibody or the antigen-binding fragment thereof comprising at least one polypeptide having an amino acid sequence of any of SEQ ID NOs: 4 to 29.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the antibody or the antigen-binding fragment thereof comprises:
an antibody heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID No: 38, 40, 42, or 44; and
an antibody light chain variable region (VL) comprising the amino acid sequence of SEQ ID No: 39, 41, 43, or 45.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the cancer is gastric cancer, liver cancer, glioblastoma, ovarian cancer, colorectal cancer, head and neck cancer, bladder cancer, renal cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma, or lung cancer.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the cancer is gastric cancer, liver cancer, glioblastoma, ovarian cancer, colorectal cancer, head and neck cancer, bladder cancer, renal cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma, or lung cancer.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the antibody or the antigen-binding fragment thereof comprises:
an antibody heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID No: 38; and
an antibody light chain variable region (VL) comprising the amino acid sequence of SEQ ID No: 39.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the antibody or the antigen-binding fragment thereof comprises:
an antibody heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID No: 40; and
an antibody light chain variable region (VL) comprising the amino acid sequence of SEQ ID No: 41.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the antibody or the antigen-binding fragment thereof comprises:
an antibody heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID No: 42; and
an antibody light chain variable region (VL) comprising the amino acid sequence of SEQ ID No: 43.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the antibody or the antigen-binding fragment thereof comprises:
an antibody heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID No: 44; and
an antibody light chain variable region (VL) comprising the amino acid sequence of SEQ ID No: 45.